The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESSO 43 | Challenges and benefits of systemic chemotherapy for peritoneal metastasis
Ignace H.J.T. de Hingh, MD, PhD, Catharina Cancer Institute, Eindhoven, Netherlands, discusses the potential benefits and drawbacks of systemic chemotherapy for treating advanced metastasis, emphasizing that while it might improve survival, it also carries risks of morbidity and mortality. He suggests that systemic therapy may not effectively target the peritoneal cavity, raising doubts about its efficacy. Furthermore, he points out that existing studies could be influenced by selection bias, questioning the overall effectiveness of this treatment strategy. This interview took place at the ESSO 43 congress in Antwerp, Belgium.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
